刘春雷, 王娟, 袁智勇, 王宝虎. 29例血管外皮瘤临床疗效分析[J]. 中国肿瘤临床, 2012, 39(22): 1843-1845，1855. DOI: 10.3969/j.issn.1000-8179.2012.22.037
引用本文: 刘春雷, 王娟, 袁智勇, 王宝虎. 29例血管外皮瘤临床疗效分析[J]. 中国肿瘤临床, 2012, 39(22): 1843-1845，1855. DOI: 10.3969/j.issn.1000-8179.2012.22.037
shu
Chunlei LIU, Juan WANG, Zhiyong YUAN, Baohu WANG. Clinical Study of 29 Patients with Hemangiopericytoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(22): 1843-1845，1855. DOI: 10.3969/j.issn.1000-8179.2012.22.037
Citation: Chunlei LIU, Juan WANG, Zhiyong YUAN, Baohu WANG. Clinical Study of 29 Patients with Hemangiopericytoma[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2012, 39(22): 1843-1845，1855. DOI: 10.3969/j.issn.1000-8179.2012.22.037
shu

29例血管外皮瘤临床疗效分析

Clinical Study of 29 Patients with Hemangiopericytoma

    摘要
  • 摘要:
      目的   血管外皮瘤是一种罕见的软组织肿瘤, 本研究旨在分析血管外皮瘤的综合治疗方法和预后。
      方法   回顾性分析1966年4月至2011年8月天津医科大学附属肿瘤医院收治的29例血管外皮瘤患者的临床资料。中位年龄为42岁(7个月~75岁), 其中男19例, 女10例。原发病灶总数为31个, 中位大小为5.2 cm×4.6 cm。
      结果   29例患者中位生存期51个月(5~252个月)。1年、3年、5年及10年生存率分别为93.1%、76.5%、67.5%和52.5%。辅助放疗组与未行辅助放疗组1年、5年、10年生存率分别为100%、87.5%、69.3%和89.5%、56.8%、34.1%。全组共11例局部复发(44%), 中位局部复发时间为9.5个月(4~120个月)。术后辅助放疗组较未行辅助放疗组局部复发率低(P=0.042), 但远处转移率没有差别(P=0.673)。术后辅助化疗未能降低远处转移率及延长总生存期。
      结论   术后辅助放疗能降低血管外皮瘤局部复发率并可延长生存期。

     

    Abstract:
      Objective   This study aimed to analyze the systemic treatment and prognosis of hemangiopericytoma (HPC).
      Methods   Clinical data of 29 patients (19 males and 10 females) who were treated in the Cancer Hospital of Tianjin Medical University between April 1966 and August 2011 were reviewed. The median age of the patients was 42 years (range: 7 months to 75 years). The total number of primary tumor was 31 and the median tumor size was 5.2 cm × 4.6 cm.
      Results   The overall median survival rate among the 29 patients was 51 months (range: 5 to 252 months); and the 1-, 3-, 5-, and 10-year survival rates of the patients were 93.1%, 76.5%, 67.5%, and 52.5%, respectively. The 1-, 5-, and 10-year survival rates of the patients who received adjuvant radiotherapy and those who did not receive adjuvant radiotherapy were 100%, 87.5%, and 69.3% as well as 89.5%, 56.8%, and 34.1%, respectively. Eleven patients (44%) had HPC recurrence and the median local recurrence time was 9.5 months (range: 4 to 120 months). Patients who received adjuvant radiotherapy after resection had a lower local recurrence rate (P=0.042) compared with those who did not receive adjuvant radiotherapy. No difference was found between the two groups (P=0.673) when distant metastases were considered. Adjuvant chemotherapy neither reduced the distant metastatic rates nor extended the overall survival rate.
      Conclusion   Adjuvant radiotherapy can reduce the local recurrence rate and may improve the overall survival rate of HPC patients.

     

    • HTML全文
    • 参考文献(18)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回